JP2004527244A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004527244A5 JP2004527244A5 JP2002577907A JP2002577907A JP2004527244A5 JP 2004527244 A5 JP2004527244 A5 JP 2004527244A5 JP 2002577907 A JP2002577907 A JP 2002577907A JP 2002577907 A JP2002577907 A JP 2002577907A JP 2004527244 A5 JP2004527244 A5 JP 2004527244A5
- Authority
- JP
- Japan
- Prior art keywords
- kinase receptor
- species
- test compound
- test
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000005962 receptors Human genes 0.000 claims 23
- 108020003175 receptors Proteins 0.000 claims 23
- 108091000080 Phosphotransferase Proteins 0.000 claims 19
- 102000020233 phosphotransferase Human genes 0.000 claims 19
- 238000000034 method Methods 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 13
- 241000894007 species Species 0.000 claims 10
- 239000008280 blood Substances 0.000 claims 5
- 210000004369 blood Anatomy 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 5
- 238000001727 in vivo Methods 0.000 claims 5
- 241000699670 Mus sp. Species 0.000 claims 3
- 230000036755 cellular response Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 241000282472 Canis lupus familiaris Species 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 241000700159 Rattus Species 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 230000026731 phosphorylation Effects 0.000 claims 2
- 238000006366 phosphorylation reaction Methods 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 230000008520 organization Effects 0.000 claims 1
- 229940068196 placebo Drugs 0.000 claims 1
- 239000000902 placebo Substances 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28077101P | 2001-04-02 | 2001-04-02 | |
| PCT/US2002/009758 WO2002079498A1 (en) | 2001-04-02 | 2002-03-29 | In vivo methods of determining activity of receptor-type kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004527244A JP2004527244A (ja) | 2004-09-09 |
| JP2004527244A5 true JP2004527244A5 (cg-RX-API-DMAC10.html) | 2005-12-22 |
Family
ID=23074563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002577907A Withdrawn JP2004527244A (ja) | 2001-04-02 | 2002-03-29 | 受容体型キナーゼ阻害剤の活性のインビボ測定方法 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1385983A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2004527244A (cg-RX-API-DMAC10.html) |
| CA (1) | CA2443144A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2002079498A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| EA017648B1 (ru) | 2007-09-14 | 2013-02-28 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны |
| JP5547194B2 (ja) | 2008-09-02 | 2014-07-09 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体 |
| JP5690277B2 (ja) | 2008-11-28 | 2015-03-25 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体 |
| AU2010232729A1 (en) | 2009-03-31 | 2011-10-20 | Arqule, Inc. | Substituted indolo-pyridinone compounds |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| CN102439015B (zh) | 2009-05-12 | 2015-05-13 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途 |
| HRP20131122T1 (hr) | 2009-05-12 | 2013-12-20 | Janssen Pharmaceuticals, Inc. | Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja |
| JP5852664B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
| ES2536433T3 (es) | 2010-11-08 | 2015-05-25 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| EP2661435B1 (en) | 2010-11-08 | 2015-08-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| ME03518B (me) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena |
| PL3096790T3 (pl) | 2014-01-21 | 2020-01-31 | Janssen Pharmaceutica, N.V. | Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| US5783568A (en) * | 1994-06-10 | 1998-07-21 | Sugen, Inc. | Methods for treating cancer and other cell proliferative diseases |
| US6271233B1 (en) * | 1999-08-10 | 2001-08-07 | Ciba Vision Corporation | Method for treating ocular neovascular diseases |
-
2002
- 2002-03-29 WO PCT/US2002/009758 patent/WO2002079498A1/en not_active Ceased
- 2002-03-29 EP EP02719386A patent/EP1385983A4/en not_active Withdrawn
- 2002-03-29 CA CA002443144A patent/CA2443144A1/en not_active Abandoned
- 2002-03-29 JP JP2002577907A patent/JP2004527244A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| He et al. | Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma | |
| Decking et al. | Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release | |
| Garshick et al. | Characterization of PCSK9 in the blood and skin of psoriasis | |
| Xu et al. | Unfolding the pathophysiological role of bioactive lysophospholipids | |
| EA201070738A1 (ru) | Композиции и способы детекции tiab | |
| Mayevsky | Mitochondrial function in vivo evaluated by NADH fluorescence | |
| Tokarzewicz et al. | SPRI biosensors for quantitative determination of matrix metalloproteinase-2 | |
| RU2010101909A (ru) | Способ выявления или лечения реакции "трансплантат против хозяина" | |
| Min et al. | Rapid and sensitive determination of the intermediates of advanced glycation end products in the human nail by ultra-performance liquid chromatography with electrospray ionization time-of-flight mass spectrometry | |
| Nishida et al. | Blood creatinine level in postmortem cases | |
| Polak | In vitro to human in vivo translation-pharmacokinetics and pharmacodynamics of quinidine | |
| Apple et al. | Analyses of creatine kinase isoenzymes and isoforms in serum to detect reperfusion after acute myocardial infarction. | |
| Baumgart et al. | In vitro and in vivo evaluation of dasatinib and imatinib on physiological parameters of pulmonary arterial hypertension | |
| JP2023096904A (ja) | 歯周病罹患リスク判定用マーカー及びその用途 | |
| Paul et al. | A review of flux considerations for in vivo neurochemical measurements | |
| Bonura et al. | Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist | |
| JP2020183958A (ja) | 歯周病バイオマーカーおよび歯周病発症の判定方法 | |
| Assenza et al. | Comparison of high-performance liquid chromatographic serum profiles of humans and dogs | |
| KR890700009A (ko) | 간기능 검사장치 | |
| Aboualizadeh et al. | Quantifying biochemical alterations in brown and subcutaneous white adipose tissues of mice using Fourier transform infrared widefield imaging | |
| KR20230051522A (ko) | 경도 인지 장애의 시험 방법, 경도 인지 장애의 시험 시약, 및 경도 인지 장애의 치료약 후보 물질의 스크리닝 방법 | |
| CN104892563B (zh) | 一种细胞色素cyp3a4酶特异性探针反应及其应用 | |
| Fujita et al. | In vivo and in vitro measurement of brain phosphodiesterase 4 in rats after antidepressant administration | |
| Gavanji et al. | Linking Experimental Models to Pathophysiology: Oxidative Stress and DNA Damage in Cardiovascular Diseases | |
| Suresh Babu et al. | Method development and measurements of endogenous serine/threonine Akt phosphorylation using capillary electrophoresis for systems biology |